Brussels, 4 December 2009 – Movetis, a Belgian pharmaceutical company, today listed on NYSE Euronext Brussels under the symbol 'MOVE'.
A total of 19,994,359 Movetis shares were admitted to trading on NYSE Euronext at an introductory price of EUR 12.25 each. The listing resulted from the offer of 13,055,583 existing shares and 6,938,776 new shares, before exercise of the over-allotment option. The amount raised by the initial public offering was EUR 85 million, excluding the over-allotment corresponding to EUR 12.75 million. At the opening, the first market price rose 2.9% to EUR 12.60, bringing the market capitalization of the company at EUR 252 million.